Cargando…

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments

BACKGROUND: Various cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated promising anti‐tumor effects. The Japanese Ministry of Health, Labour and Welfare has issued a warning about interstitial lung diseases as an adverse effect of CDK4/6 inhibitors. However, a large‐scale evaluation o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nawa, Hideki, Niimura, Takahiro, Yagi, Kenta, Goda, Mitsuhiro, Zamami, Yoshito, Ishizawa, Keisuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789605/ https://www.ncbi.nlm.nih.gov/pubmed/33939324 http://dx.doi.org/10.1002/cnr2.1402

Ejemplares similares

Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects
por: Nawa, Hideki, et al.
Publicado: (2021)

Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects
por: Nawa, Hideki, et al.
Publicado: (2022)

Drug-Repositioning Approaches Based on Medical and Life Science Databases
por: Zamami, Yoshito, et al.
Publicado: (2021)

Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
por: Okada, Naoto, et al.
Publicado: (2020)

Effects of 5‐HT(₃) receptor antagonists on cisplatin‐induced kidney injury
por: Goda, Mitsuhiro, et al.
Publicado: (2021)

Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage
por: Yoshioka, Toshihiko, et al.
Publicado: (2023)

Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR‐ABL inhibitor use by using an adverse drug event reporting database
por: Okada, Naoto, et al.
Publicado: (2018)

Investigation of drugs affecting hypertension in bevacizumab‐treated patients and examination of the impact on the therapeutic effect
por: Yagi, Kenta, et al.
Publicado: (2020)

Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
por: Kanda, Masaya, et al.
Publicado: (2022)

Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis( )
por: Chuma, Masayuki, et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Preventive Effects of Quercetin against the Onset of Atherosclerosis-Related Acute Aortic Syndromes in Mice
por: Kondo, Masateru, et al.
Publicado: (2020)

Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases
por: Hagiwara, Hiromi, et al.
Publicado: (2020)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
por: Calucică, Daniela Maria, et al.
Publicado: (2022)

Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study
por: Sakurada, Takumi, et al.
Publicado: (2022)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database
por: Zamami, Yoshito, et al.
Publicado: (2019)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
por: Gebbia, Vittorio, et al.
Publicado: (2023)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
por: Mlinarić, Zvonimir, et al.
Publicado: (2022)

Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia
por: Sato, Shiho, et al.
Publicado: (2017)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
por: Wender, Isabella O., et al.
Publicado: (2020)

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
por: Pandey, Kamal, et al.
Publicado: (2022)

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
por: Chen, Yucherng, et al.
Publicado: (2021)

A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
por: Imakura, Takeshi, et al.
Publicado: (2023)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
por: Law, Ernest H, et al.
Publicado: (2023)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
por: Cejuela, Mónica, et al.
Publicado: (2023)

A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic
por: Yagi, Kenta, et al.
Publicado: (2022)

Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation
por: Takada, Shinya, et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

Evaluation of pharmaceutical lifesaving skills training oriented pharmaceutical intervention
por: Zamami, Yoshito, et al.
Publicado: (2016)

Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis
por: Higashionna, Tsukasa, et al.
Publicado: (2023)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation
por: MAYLINA, Leni, et al.
Publicado: (2022)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
por: Mao, Yan, et al.
Publicado: (2023)

Hydrocortisone administration was associated with improved survival in Japanese patients with cardiac arrest
por: Niimura, Takahiro, et al.
Publicado: (2017)

Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells
por: Konaka, Ken, et al.
Publicado: (2017)

Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System
por: Okada, Naoto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_48crip0i5a17rncnhrdepq5e93